Henry Jemil Esber insider trades: Innovus Pharmaceuticals (INNV) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Henry reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 23, 2017 | INNV | ↑ Buy | 100,000 | $0.09 | $9K | Direct | Nov 27, 2017 (4d) |
| Mar 18, 2015 | BTHE | ↑ Buy | 9,000 | $0.20 | $2K | Direct | Mar 20, 2015 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other INNV insiders
Open-market trades in the last 12 months
About Henry Jemil Esber's insider trades
Henry Jemil Esber is a director at Innovus Pharmaceuticals (INNV). Since Mar 18, 2015, Henry has reported 2 open-market purchases worth $11K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (38 filings), other transactions (2 filings), gifts (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INNV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.